International Stem Cell CORP — fact timeline

Source-grounded facts extracted from International Stem Cell CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.

Debt Financings September 16, 2025, 7:59 PM ET

International Stem Cell CORP amended loan of $2,500,000 with Dr. Andrey Semechkin at 5.5% per annum maturing September 15, 2026.

“On September 15, 2025, International Stem Cell Corporation (the “Company”) and Dr. Andrey Semechkin agreed to extend (until September 15, 2026) the maturity date of the loan (in the principal amount of $2,500,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated September 15, 2024 (the “Original Note”), and which would have been due on September 15, 2024.”

Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.